You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • AB0420 Secondary Efficacy Outcomes from a Phase 3 Study Support Clinical Equivalence Between BOW015 and Infliximab in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses

Citation Tools

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Rheumatoid arthritis - anti-TNF therapy
AB0420 Secondary Efficacy Outcomes from a Phase 3 Study Support Clinical Equivalence Between BOW015 and Infliximab in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kay J, Chopra A, Chandrashekara S, et al
AB0420 Secondary Efficacy Outcomes from a Phase 3 Study Support Clinical Equivalence Between BOW015 and Infliximab in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses
Annals of the Rheumatic Diseases 2015;74:1034.